Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a large growth in short interest in June. As of June 15th, there was short interest totaling 765,484 shares, a growth of 231.8% from the May 31st total of 230,679 shares. Based on an average daily trading volume, of 346,077 shares, the short-interest ratio is presently 2.2 days. Approximately 4.9% of the shares of the stock are sold short.

Institutional Trading of Cel-Sci

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Cel-Sci by 59.7% during the third quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after buying an additional 109,352 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after buying an additional 39,190 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Cel-Sci by 133.0% during the 1st quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock valued at $115,000 after acquiring an additional 20,484 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Cel-Sci by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock valued at $417,000 after acquiring an additional 18,432 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Cel-Sci during the 4th quarter worth $83,000. 12.08% of the stock is owned by institutional investors and hedge funds.

Cel-Sci Trading Down 2.7%

Shares of Cel-Sci stock opened at $1.08 on Tuesday. The business has a fifty day simple moving average of $1.75 and a 200-day simple moving average of $3.68. Cel-Sci has a fifty-two week low of $0.89 and a fifty-two week high of $13.48. The firm has a market cap of $18.88 million, a price-to-earnings ratio of -0.11 and a beta of 0.54. The company has a quick ratio of 0.54, a current ratio of 0.60 and a debt-to-equity ratio of 0.64.

Cel-Sci (NYSEAMERICAN:CVM) last released its earnings results on Friday, May 15th. The company reported ($0.67) earnings per share (EPS) for the quarter.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.